Heinz Ludwig

Active 1982–2025

149
Papers
42,234
Citations
103
h-index
148
i10-index

Citations

Citations per year for Heinz Ludwig1948: 3 citations1985: 1 citations1986: 4 citations1987: 1 citations1988: 3 citations1989: 1 citations1990: 1 citations1991: 4 citations1992: 16 citations1993: 14 citations1994: 21 citations1995: 24 citations1996: 24 citations1997: 27 citations1998: 44 citations1999: 42 citations2000: 43 citations2001: 66 citations2002: 54 citations2003: 61 citations2004: 57 citations2005: 61 citations2006: 83 citations2007: 107 citations2008: 144 citations2009: 181 citations2010: 226 citations2011: 273 citations2012: 243 citations2013: 233 citations2014: 256 citations2015: 250 citations2016: 326 citations2017: 342 citations2018: 284 citations2019: 1,248 citations2020: 1,270 citations2021: 1,271 citations2022: 877 citations2023: 606 citations2024: 1,137 citations2025: 475 citations2026: 16 citations1949–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,989 citing papers, 23.4% of this breakdownGermany: 818 citing papers, 6.4% of this breakdownItaly: 817 citing papers, 6.4% of this breakdownUnited Kingdom: 780 citing papers, 6.1% of this breakdownFrance: 712 citing papers, 5.6% of this breakdownSpain: 691 citing papers, 5.4% of this breakdownChina: 635 citing papers, 5% of this breakdownCanada: 434 citing papers, 3.4% of this breakdownNetherlands: 430 citing papers, 3.4% of this breakdownGreece: 390 citing papers, 3.1% of this breakdownAustralia: 329 citing papers, 2.6% of this breakdownBelgium: 326 citing papers, 2.5% of this breakdown
0%23.4%Other 26.7%

Fields

  • Medicine83.7%
  • Biochemistry, Genetics and Molecular Biology10.8%
  • Immunology and Microbiology2.2%
  • Computer Science0.5%
  • Neuroscience0.4%
  • Chemistry0.4%
  • Other2%

Topics

  • Multiple Myeloma Research and Treatments19%
  • Protein Degradation and Inhibitors7.8%
  • Peptidase Inhibition and Analysis4.2%
  • Cancer Treatment and Pharmacology3.3%
  • CAR-T cell therapy research2.4%
  • Ubiquitin and proteasome pathways2.2%
  • Other61.1%

Coauthors

All papers

Open in search
  1. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 cited by 2,995

  2. International Staging System for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2005 cited by 2,918

  3. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 178

  4. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

    Authors: , , , , , , , , , , , , - Blood Cancer Journal 2023 cited by 179

  5. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 1,034

  6. International uniform response criteria for multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the International Myeloma Working Group - Leukemia 2006 cited by 2,639

  7. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  8. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 cited by 275

  9. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jesús F. San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao Prabhala, Phillip McCarthy, Nikhil C. Munshi - The Lancet Haematology 2022 cited by 191

  10. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2010 cited by 876

  11. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 1,324

  12. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 762

  13. Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma

    Authors: , , , , , , , , , , , - European Journal of Clinical Investigation 2012 cited by 127

  14. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  15. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

    Authors: , , , , , , - Journal of Hematology & Oncology 2020 cited by 171

  16. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashutosh Wechalekar, Brendan M. Weiss, Samih H. Nasr - Nature Reviews Nephrology 2018 cited by 534

  17. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment

    Authors: , , , , - The Oncologist 2020 cited by 195

  18. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark‐David Levin, Gerard M.J. Bos, Heinz Ludwig, Sara Aquino, Anna Morelli, Ka Lung Wu, Rinske Boersma, Roman Hájek, Marc Durian, Peter A. von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf‐Henrik Mellqvist, Marinus van Marwijk Kooy, Monique C. Minnema, Caroline M.P.W. Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld - The Lancet Haematology 2020 cited by 384

  19. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2019 cited by 230

  20. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon - New England Journal of Medicine 2014 cited by 786

  21. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 121

  22. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2017 cited by 277

  23. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wee Joo Chng - The Lancet Oncology 2015 cited by 849

  24. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 cited by 354